Tap
#Rheumatology
Hashtag Rheumatology
every day
every day
Remibrutinib phase 2 trial reduce ESSDAI
Donald Thomas
Share Talk
Visit
ard.bmj.com
to learn more
February 15, 2024
12 hr
Log in
Sign Up
Channels
Discovery
Cardiology
every day
COVID
every day
Dermatology
every day
Endocrinology
every day
endo22
ata22
Gastroenterology
every day
Hematology
every day
ash2024
Hepatology
every day
Nephrology
every day
asn24
kidneywk22
nkfscm22
asn23
Oncology
every day
esmo22
Ophthalmology
every day
aao23
dry_eye_disease
amd
visions2024
arvo2024
aao22
arvo22
aao21
wio22
Primary Care
every day
Pulmonology
every day
Rheumatology
every day
acr23
acr24
acr22
hiv
Urology
every day
Speaker
Share
Remibrutinib phase 2 trial reduce ESSDAI
Twitter
Facebook
Linkedin
Reddit
Email
Copy Link
Remibrutinib phase 2 trial reduce ESSDAI
Log in
|
Sign Up
Get Medspoke on your Devices
Privacy Policy
Terms of Services
Copyright Center
Community Guideline
Support
Hear
Speakers
Talk
Profile
Hear here
We'd love hear from you, but you have to log in first
Log In
or
Sign Up
Privacy Policy
Why are you reporting this TALK?
